苯佐那酯暴露的20年单毒物中心回顾:结局与处理
该研究回顾了2000年1月1日至2019年12月31日威斯康星毒物中心接报的全部苯佐那酯暴露,排除病历不完整者后纳入265例。故意暴露106例中23例(22%)出现至少一种严重不良效应(癫痫发作、心电图改变、昏迷或中枢神经系统抑制、死亡),40例(38%)住院;意外暴露143例中仅1例(0.7%)出现严重不良效应,3例(2%)住院;77例意外儿童暴露无严重不良效应,2例(3%)住院。研究期间共2例死亡(0.8%),均为故意暴露。作者结论:故意暴露更常需要显著治疗干预并造成更高严重毒性,意外暴露未导致临床显著不良效应,成人意外暴露可考虑居家管理。
要点
- 故意暴露106例中23例(22%)出现严重不良效应(癫痫发作、心电图改变、昏迷或中枢抑制、死亡),40例(38%)住院。
- 意外暴露143例中仅1例(0.7%)出现严重不良效应,3例(2%)住院;77例意外儿童暴露无严重不良效应,2例(3%)住院。
- 研究期间共2例死亡(0.8%),均为故意暴露。
- 除支持治疗外,没有一种治疗干预被持续使用(原文:No therapeutic interventions beyond supportive care were consistently employed)。
- 作者认为:尽管苯佐那酯可导致严重毒性,成人意外暴露可考虑居家管理。
适用人群与场景
- 2000年1月1日至2019年12月31日向威斯康星毒物中心报告的苯佐那酯暴露,病历不完整者被排除,最终纳入265例。
- 暴露者以女性为主(162/265;61%),中位年龄19岁(IQR:4-39岁)。
- 包括故意暴露106例(40%)、意外暴露143例(54%)、仅不良反应16例。
- 意外儿童暴露77例。
处置流程与药物剂量
- 潜在救命治疗包括抗癫痫药、抗心律失常药、血管升压药、碳酸氢钠或静脉脂质治疗,但原文报告除支持治疗外没有一种治疗干预被持续使用。
- 作者认为成人意外暴露可考虑居家管理。
红旗征与不能漏的情况
- 故意暴露可能发生癫痫发作、心电图改变、昏迷或中枢神经系统抑制、死亡,106例故意暴露中23例(22%)出现至少一种严重不良效应。
- 研究期间2例死亡(0.8%)均为故意暴露。
研究设计与关键结果
- 研究类型:单中心回顾性病例复习(威斯康星毒物中心),时间2000年1月1日至2019年12月31日;共接到313次呼叫,排除48例,纳入265例。
- 主要结局为严重不良效应(癫痫发作、心电图改变、昏迷或中枢神经系统抑制、死亡)的发生率。
- 故意暴露106/265(40%)中23例(22%)出现至少一种严重不良效应,40例(38%)住院。
- 意外暴露143/265(54%)中1例(0.7%)出现严重不良效应,3例(2%)住院。
- 77例意外儿童暴露中无严重不良效应,2例(2/77;3%)住院。
- 仅不良反应16例;研究期间共2例死亡(0.8%),均为故意暴露。
- 除支持治疗外,没有一种治疗干预被持续使用。
证据类型、等级与局限
- 证据类型:单中心回顾性病例复习。
- 局限:原文未报告局限性。
对床旁实践的改变
- 故意苯佐那酯暴露更常需要显著治疗干预并造成更高严重毒性,应重视其癫痫发作、心电图改变、昏迷或中枢抑制风险。
- 意外暴露(包括77例意外儿童暴露)未出现严重不良效应,作者认为成人意外暴露可考虑居家管理。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Benzonatate is an antitussive with sodium channel blocking properties that may cause seizures, dysrhythmias, and death in overdose. Limited data describe the medical outcomes of benzonatate exposures, and no standard treatment guidelines exist for managing benzonatate toxicity. We characterized clinical outcomes and management of benzonatate exposures over a 20-year period at the Wisconsin Poison Center.
METHODS: This retrospective case review examined all benzonatate exposures reported to a single regional poison center from January 1, 2000 through December 31, 2019. Exposures were excluded if the medical record was incomplete. The primary outcome was the rate of serious adverse effects, defined as seizure, electrocardiogram changes, coma or central nervous system depression, or death. Potential life-saving treatments (antiepileptics, antidysrhythmics, vasopressors, sodium bicarbonate, or intravenous lipid therapy) were also assessed.
RESULTS: A total of 313 calls were received with 48 exposures excluded, leaving 265 exposures included for analysis. Most exposures were female (162/265; 61%) with a median age of 19 years (IQR: 4-39 years). Sixteen exposures were adverse reactions only. Of intentional exposures (106/265; 40%), 23 (22%) experienced at least one serious adverse effect and 40 (38%) were hospitalized. Of unintentional exposures (143/265, 54%), one (0.7%) experienced a serious adverse effect and three (2%) were hospitalized. Regarding 77 unintentional pediatric exposures, none experienced a serious adverse effect, with two (2/77; 3%) hospitalized. Two deaths (0.8%) occurred during the study period; both were intentional exposures.
DISCUSSION: While severe outcomes are possible after intentional exposures, unintentional exposures rarely exhibited serious toxicities. No therapeutic interventions beyond supportive care were consistently employed.
CONCLUSIONS: Intentional exposures to benzonatate more commonly warranted significant therapeutic interventions and caused a higher incidence of serious toxicity. Unintentional exposures did not result in clinically significant adverse effects. Although benzonatate can result in serious toxicity, adults with unintentional exposures may be candidates for home management.
参考来源
- Cicci CD, Theobald J, Stanton M, et al. Outcomes of benzonatate exposures reported to a single United States poison center: a 20-year review. Clin Toxicol (Phila). 2025. PMID: 40511470. doi:10.1080/15563650.2025.2512817
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。